NovaBridge Biosciences (NBP) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 27, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Apr 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NBP SEC filings page.
This page shows NovaBridge Biosciences (NBP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
NovaBridge is funding a larger development effort while losses persist, with cash use improving but liabilities rising faster than equity.
Operating cash use narrowed from$52.7M in FY2024 to$20.6M in FY2025 even as the reported loss worsened. That divergence, plus only$7K of capital expenditures, indicates accounting charges—not asset investment—drove much of the loss, while free cash flow essentially matched operating cash flow.
R&D increased
Liabilities grew
Financial Health Signals
NovaBridge Biosciences does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
NovaBridge Biosciences passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
NovaBridge Biosciences reported a net loss of $46.3M while operations used $20.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
NovaBridge Biosciences earned -$0.13 per diluted share (EPS) in Q4 2025. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Not reported for Q4 2025.
Not reported for Q4 2025.
Not reported for Q4 2025.
Cash & Balance Sheet
NovaBridge Biosciences recorded an outflow of $14.6M in free cash flow in Q4 2025, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 893.7%.
NovaBridge Biosciences held $210.6M in cash as of Q4 2025; no long-term debt figure is on record for that period.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
NovaBridge Biosciences reported no capital expenditure in Q4 2025. This represents a decrease of 100.0% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q4 2025.
Not reported for Q4 2025.
NBP Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, Diluted Shares (Avg).
NBP Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q3'256-K | Q2'256-K | Q4'2420-F | Q3'246-K | Q4'2320-F | Q4'2220-F | Q2'226-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $260.5M+22.5% | $277.4M | $206.7M | $212.7M-42.4% | N/A | $368.9M-37.5% | $590.6M-32.8% | $745.2M |
| Current Assets | $217.5M+23.1% | $232.8M | $167.6M | $176.7M-46.4% | N/A | $329.9M-37.3% | $525.8M-29.9% | $644.2M |
| Cash & Equivalents | $210.6M+208.6% | $228.1M+187.5% | $165.4M | $68.3M-76.6% | $79.3M | $291.5M-15.0% | $342.9M-38.0% | $554.0M |
| Short-Term Investments | $210K-99.8% | $210Kn/m | $210K | $105.1M+419.9% | $0 | $20.2M-40.8% | $34.1M-71.1% | $31.5M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $76K |
| Long-Term Investments | $0-100.0% | $40.3Mn/m | $34.5M | $30.8Mn/m | $0 | $0n/m | $0n/m | $0 |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | $23.6M-7.6% | $24.3M |
| Total Liabilities | $29.6M+156.8% | $18.5M | $10.0M | $11.5M-90.9% | N/A | $126.3M-25.1% | $168.7M+3.2% | $145.6M |
| Current Liabilities | $26.9M+218.1% | $16.1M | $7.3M | $8.5M-85.5% | N/A | $58.1M-47.1% | $109.9M+12.3% | $88.1M |
| Non-Current Liabilities | $2.7M-12.4% | $2.4M | $2.6M | $3.1M-95.5% | N/A | $68.2M+16.0% | $58.8M-10.3% | $57.6M |
| Total Equity | $230.9M+14.8% | $258.9M+17.8% | $196.7M | $201.2M-17.1% | $219.7M | $242.6M-41.9% | $417.8M-41.6% | $599.6M |
| Retained Earnings | -$1.3Bn/m | -$1.3B | -$1.3B | -$1.3Bn/m | N/A | -$1.3Bn/m | -$994.9Mn/m | -$806.5M |
Not reported in any period shown, so not listed: Long-Term Debt.
NBP Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q3'256-K | Q2'256-K | Q4'2420-F | Q3'246-K | Q4'2320-F | Q4'2220-F | Q2'226-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$14.6Mn/m | $1.8M-78.2% | N/A | -$10.9M | $8.4M | N/A | N/A | N/A |
| Depreciation & Amortization | $15K | $17K-15.0% | N/A | N/A | $20K | N/A | N/A | N/A |
| Capital Expenditures | $0-100.0% | $0-100.0% | N/A | $38K | $1K | N/A | N/A | N/A |
| Free Cash Flow | -$14.6Mn/m | $1.8M-78.2% | N/A | -$11.0M | $8.4M | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | $0 | $0 | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Stock-Based Compensation, Investing Cash Flow, Financing Cash Flow, Dividends Paid.
NBP Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Debt-to-Equity, Asset Turnover, FCF Margin.
Where NovaBridge Biosciences Ranks
Frequently Asked Questions
Is NovaBridge Biosciences profitable?
No, NovaBridge Biosciences (NBP) reported a net loss of $46.3M in fiscal year 2025.
What is NovaBridge Biosciences's EBITDA?
NovaBridge Biosciences (NBP) had EBITDA of -$94.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is NovaBridge Biosciences's return on equity (ROE)?
NovaBridge Biosciences (NBP) has a return on equity of -20.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is NovaBridge Biosciences's free cash flow?
NovaBridge Biosciences (NBP) recorded an outflow of $20.6M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is NovaBridge Biosciences's operating cash flow?
NovaBridge Biosciences (NBP) recorded an outflow of $20.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are NovaBridge Biosciences's total assets?
NovaBridge Biosciences (NBP) had $260.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are NovaBridge Biosciences's capital expenditures?
NovaBridge Biosciences (NBP) invested $7K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does NovaBridge Biosciences spend on research and development?
NovaBridge Biosciences (NBP) invested $62.9M in research and development during fiscal year 2025.
What is NovaBridge Biosciences's current ratio?
NovaBridge Biosciences (NBP) had a current ratio of 8.09 as of fiscal year 2025, which is generally considered healthy.
What is NovaBridge Biosciences's liabilities-to-equity ratio?
NovaBridge Biosciences (NBP) had a liabilities-to-equity ratio of 0.13 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is NovaBridge Biosciences's return on assets (ROA)?
NovaBridge Biosciences (NBP) had a return on assets of -17.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is NovaBridge Biosciences's P/E ratio?
NovaBridge Biosciences (NBP) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $145.1M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is NovaBridge Biosciences's price-to-sales ratio?
NovaBridge Biosciences (NBP) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $145.1M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is NovaBridge Biosciences's Piotroski F-Score?
NovaBridge Biosciences (NBP) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are NovaBridge Biosciences's earnings high quality?
NovaBridge Biosciences (NBP) reported a net loss of $46.3M while operations used $20.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.